Asahi Kasei Pharma Corporation
Quick facts
Phase 3 pipeline
- AK156 · Oncology
AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses. - AK1820
AK1820 is an investigational therapeutic targeting immune or inflammatory pathways, though its precise mechanism remains proprietary. - Cyclophosphamide (CTX) · Oncology, Immunology
Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and triggering apoptosis in rapidly dividing cells. - Mizoribine (MZR) · Immunology; Transplantation
Mizoribine inhibits inosine monophosphate dehydrogenase (IMPDH) to suppress guanine nucleotide synthesis and reduce T and B cell proliferation.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: